GlassScriptPhysician profile
Julian M Vassay
NPI 1003922782
$3,559.59
in general payments reported to CMS, 2019-2025
25 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $458 · 2021: $102 · 2022: $280 · 2023: $601 · 2024: $534 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $687.79 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $626.98 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $538.70 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $356.44 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.59 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $170.51 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $146.11 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $114.35 | 2019-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $111.97 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $86.48 | 2019-2022 | |
| Astellas Pharma US INC | $68.79 | 2019-2020 | |
| Daiichi Sankyo INC. | $60.18 | 2022-2023 | Injectafer |
| Glaxosmithkline, LLC. | $48.80 | 2019-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $37.44 | 2019-2022 | |
| Insulet Corporation | $37.41 | 2024 | Omnipod |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.28 | 2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $31.51 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.79 | 2023 | Nuedexta |
| Vertex Pharmaceuticals Incorporated | $19.26 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $18.79 | 2022 | |
| Amarin Pharma, INC. | $17.54 | 2019 | |
| Vifor Pharma, INC. | $16.85 | 2019 | |
| Sanofi Pasteur INC. | $14.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.68 | 2023 | |
| Mylan Specialty L.P. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Vassay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.